Medscape2d
Pheochromocytoma: Recommendations for Clinical Practice from the First International Symposium
The First International Symposium on Pheochromocytoma ... Localization studies should only follow reasonable clinical evidence of a tumor. Preoperative pharmacologic blockade of circulatory ...
Monthly Prescribing Reference6d
Belzutifan Gets Priority Review for Advanced Pheochromocytoma and Paraganglioma
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...
Medscape16y
Bilateral Optic Disc Swelling as the Presenting Sign of Pheochromocytoma in a Child
Bilateral optic disc swelling is an important clinical sign that can reflect a ... or as a first consultation by a patient with visual symptoms. The diagnosis of idiopathic intracranial ...
Contract Pharma7d
Merck’s WELIREG Accepted for Priority Review by FDA for Pheochromocytoma and Paraganglioma
The supplemental new drug application is based on data from the Phase 2 LITESPARK-015 trial.
Cure Today5d
FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...
Targeted Oncology5d
FDA Grants Belzutifan Priority Review For Advanced Pheochromocytoma and Paraganglioma
The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.